Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer : significance of pre-treatment and post-resection RAS mutations
| dc.contributor.author | Gollins, Simon | |
| dc.contributor.author | West, Nick | |
| dc.contributor.author | Sebag-Montefiore, David | |
| dc.contributor.author | Myint, Arthur Sun | |
| dc.contributor.author | Saunders, Mark | |
| dc.contributor.author | Susnerwala, Shabbir | |
| dc.contributor.author | Quirke, Phil | |
| dc.contributor.author | Essapen, Sharadah | |
| dc.contributor.author | Samuel, Leslie | |
| dc.contributor.author | Sizer, Bruce | |
| dc.contributor.author | Worlding, Jane | |
| dc.contributor.author | Southward, Katie | |
| dc.contributor.author | Hemmings, Gemma | |
| dc.contributor.author | Tinkler-Hundal, Emma | |
| dc.contributor.author | Taylor, Morag | |
| dc.contributor.author | Bottomley, Daniel | |
| dc.contributor.author | Chambers, Philip | |
| dc.contributor.author | Lawrie, Emma | |
| dc.contributor.author | Lopes, Andre | |
| dc.contributor.author | Beare, Sandy | |
| dc.contributor.institution | University of Aberdeen.Aberdeen Centre for Evaluation | en |
| dc.date.accessioned | 2018-04-02T08:44:06Z | |
| dc.date.available | 2018-04-02T08:44:06Z | |
| dc.date.issued | 2017-10-24 | |
| dc.description | This work was funded by Cancer Research UK Bobby Moore Fund (ref C23134A9353). Merck Serono supplied free cetuximab and an educational grant and Pfizer gave free irinotecan and an educational grant. Neither Merck Serono or Pfizer was involved in study design, data analysis or manuscript preparation or had access to study data. Central trial coordination was by Cancer Research UK and University College London Cancer Trials Centre, including data collection and statistical analyses. The Pathology and Tumour Biology laboratory is supported by grants from Yorkshire Cancer Research, the Pathological Society of Great Britain and Ireland, the Academy of Medical Sciences, The Medical Research Council and a National Institute of Health Research Senior Investigator Award. SG was a National Institute for Social Care and Health Research Academic Health Science Collaboration Clinical Research Fellow. | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 9 | |
| dc.format.extent | 302187 | |
| dc.identifier | 117910179 | |
| dc.identifier | e173c88d-c840-4387-87cf-cb6c0481390f | |
| dc.identifier | 85033408230 | |
| dc.identifier.citation | Gollins, S, West, N, Sebag-Montefiore, D, Myint, A S, Saunders, M, Susnerwala, S, Quirke, P, Essapen, S, Samuel, L, Sizer, B, Worlding, J, Southward, K, Hemmings, G, Tinkler-Hundal, E, Taylor, M, Bottomley, D, Chambers, P, Lawrie, E, Lopes, A & Beare, S 2017, 'Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer : significance of pre-treatment and post-resection RAS mutations', British Journal of Cancer, vol. 117, pp. 1286-1294. https://doi.org/10.1038/bjc.2017.294 | en |
| dc.identifier.doi | 10.1038/bjc.2017.294 | |
| dc.identifier.issn | 0007-0920 | |
| dc.identifier.other | ORCID: /0000-0002-8402-8670/work/50559792 | |
| dc.identifier.uri | http://hdl.handle.net/2164/10275 | |
| dc.identifier.vol | 117 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | British Journal of Cancer | en |
| dc.subject | SDG 3 - Good Health and Well-being | en |
| dc.subject | locally advanced rectal cancer | en |
| dc.subject | cetuximab-containing chemoradiation | en |
| dc.subject | RAS mutations | en |
| dc.subject | intra-tumoural clonal heterogeneity | en |
| dc.subject | treatment response | en |
| dc.subject | next generation sequencing | en |
| dc.subject | RC0254 Neoplasms. Tumors. Oncology (including Cancer) | en |
| dc.subject | Cancer Research UK | en |
| dc.subject | C23134A9353 | en |
| dc.subject.lcc | RC0254 | en |
| dc.title | Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer : significance of pre-treatment and post-resection RAS mutations | en |
| dc.type | Journal article | en |